Compare CRVL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVL | ARQT |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 1991 | 2020 |
| Metric | CRVL | ARQT |
|---|---|---|
| Price | $69.62 | $29.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.83 |
| AVG Volume (30 Days) | 179.6K | ★ 1.8M |
| Earning Date | 02-03-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.11 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $933,841,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | N/A | $30.74 |
| P/E Ratio | $33.74 | ★ N/A |
| Revenue Growth | 10.43 | ★ 129.21 |
| 52 Week Low | $65.47 | $11.13 |
| 52 Week High | $128.61 | $31.77 |
| Indicator | CRVL | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 52.91 |
| Support Level | $65.47 | $27.71 |
| Resistance Level | $69.56 | $30.26 |
| Average True Range (ATR) | 1.62 | 1.11 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 67.32 | 56.13 |
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.